DIA 48th Annual Meeting
Click here to go to the previous page
Drug Development Strategies for Integrating Academia, Non-governmental Organizations (NGOs), and Industry Based on Experience in Neglected and Infectious Diseases
Track
:
Track 18: Rare/Neglected Diseases
Program Code:
122
Date:
Monday, June 25, 2012
Time:
10:00 AM to 11:30 AM
EST
CHAIR
:
Melynda Watkins, Clinton Health Access Initiative (CHAI), United States
PRESENTER
(S):
Robert Jacobs, SCYNEXIS, Inc., United States Melynda Watkins, Clinton Health Access Initiative (CHAI), United States Eric Easom, Anacor Pharmaceuticals, United States
Description
This session will describe drug development strategies for integrating academia, non-governmental organizations (NGOs), and industry based on experience for the development of drugs for neglected and infectious diseases in the global health arena.
Learning Objectives:
Analyze the area of neglected disease drug development to determine program designs to facilitate go/no-go decisions
Describe the strategies for virtual drug development to facilitate programs in these diseases
Identify strategies for partnering to facilitate programs in developing nations.
Learning Objectives:
Analyze the area of neglected disease drug development to determine program designs to facilitate go/no-go decisions
Describe the strategies for virtual drug development to facilitate programs in these diseases
Identify strategies for partnering to facilitate programs in developing nations.
This session is a part of:
Handout Online
